ECS16
THE CORNEAT ESHUNT, CORNEAT VISION’S REVOLUTIONARY GLAUCOMA DRAINAGE DEVICE: EXTENDING MINIMALLY INVASIVE SURGERY TO SEVERE AND REFRACTORY PATIENTS
G. Litvin1,*
1CorNeat Vision, Raanana, Israel
CorNeat Vision has developed a number of medical devices, first and foremost the CorNeat eShunt, a revolutionary glaucoma drainage device, that provides, for the first time, a long-lasting, minimally invasive solution for severe and refractory glaucoma patients. This device is designed to regulate the intraocular pressure and addresses the shortcomings of existing solutions. It is efficacious and stable immediately post-op as resistance to flow is dictated by its inlet and tube design and not by a valve or scarring around the outlet. The CorNeat eShunt outlet is uniquely positioned in the intraconal space, an area that does not scar and clog over time. The positive pressure (approx. 4mmHg) in this area reduces the risk of hypotony. The fat in the intraconal space can absorb the drained aqueous humour, without creating a bleb. The device seamlessly integrates with the ocular tissue using an integral non-degradable tissue-integrating patch. This significantly shortens and simplifies the surgical procedure and minimizes the risk of tube exposure. This, plus the fact that there’s no reservoir, reduces the surgical procedure to approximately 20 minutes.
CorNeat Vision products and solutions leverage a unique permanent tissue-integrating material technology, CorNeat EverMatrix™, to address unmet needs in ophthalmology and beyond. The CorNeat EverMatrix™, is a non-degradable biomaterial that enables implants to avoid the foreign body response—an immunological process leading to the rejection and degradation of implanted devices. This challenge fundamentally affects their performance, durability, and therapeutic utility.
The EverMatrix™ seamlessly and permanently embeds with living soft and bone tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants that can:
– Bio-mechanically integrate with surrounding tissue
– Permanently reinforce soft tissue and accelerate healing
– Act as a membrane for guided soft tissue and bone regeneration
– Conceal irritating implants
– Enable sensors to continuously remain in contact with surrounding tissue
The EverMatrix™ is also set to displace harvested and processed human and animal tissues, including scaffolds and extracellular matrices, used in a variety of surgical procedures across diversified fields of medicine.
The features and benefits of the EverMatrix™ were proven histologically and clinically in various pre-clinical and clinical trials, including in humans. Findings demonstrate full fibroblast colonization and abundant collagen deposition with no encapsulation, rendering the EverMatrix™ an integral part of the surrounding tissue. The recent FDA 510(k) clearance of our first product, the CorNeat EverPatch, a synthetic tissue substitute for ocular surface surgeries, continues to validate the usage of the EverMatrix™.